SE9301830D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9301830D0
SE9301830D0 SE19939301830A SE9301830A SE9301830D0 SE 9301830 D0 SE9301830 D0 SE 9301830D0 SE 19939301830 A SE19939301830 A SE 19939301830A SE 9301830 A SE9301830 A SE 9301830A SE 9301830 D0 SE9301830 D0 SE 9301830D0
Authority
SE
Sweden
Prior art keywords
new compounds
improved
omeprazole
enantiomer
manufacture
Prior art date
Application number
SE19939301830A
Other languages
English (en)
Swedish (sv)
Inventor
Lennart *Lindberg Per
P O *Von Unge Sverker
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9301830(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ab Astra filed Critical Ab Astra
Priority to SE19939301830A priority Critical patent/SE9301830D0/xx
Publication of SE9301830D0 publication Critical patent/SE9301830D0/xx
Priority to IS4161A priority patent/IS1854B/is
Priority to TW083104255A priority patent/TW389761B/zh
Priority to HR940307A priority patent/HRP940307B1/xx
Priority to LTIP1941A priority patent/LT3287B/lt
Priority to IL10968494A priority patent/IL109684A/en
Priority to ZA943557A priority patent/ZA943557B/xx
Priority to DZ940055A priority patent/DZ1785A1/fr
Priority to MA23521A priority patent/MA23210A1/fr
Priority to DE69435220T priority patent/DE69435220D1/de
Priority to DK00108480.5T priority patent/DK1020461T4/en
Priority to US08/256,174 priority patent/US5693818A/en
Priority to RU95105587A priority patent/RU2137766C1/ru
Priority to ES94917244T priority patent/ES2099047T3/es
Priority to DE69426254T priority patent/DE69426254T2/de
Priority to SG1996008770A priority patent/SG49283A1/en
Priority to DK00108479T priority patent/DK1020460T3/da
Priority to TNTNSN94058A priority patent/TNSN94058A1/fr
Priority to AT94917244T priority patent/ATE197452T1/de
Priority to CZ1995202A priority patent/CZ287876B6/cs
Priority to KR1019950700365A priority patent/KR100337274B1/ko
Priority to PCT/SE1994/000509 priority patent/WO1994027988A1/en
Priority to SI9420002A priority patent/SI9420002B/sl
Priority to NZ266915A priority patent/NZ266915A/en
Priority to JP50055395A priority patent/JP3549111B2/ja
Priority to CN94190335A priority patent/CN1055469C/zh
Priority to SI9420085A priority patent/SI22752B/sl
Priority to AU69024/94A priority patent/AU676337C/en
Priority to SK101-95A priority patent/SK282524B6/sk
Priority to EP00108480.5A priority patent/EP1020461B2/en
Priority to EP94917244A priority patent/EP0652872B1/en
Priority to YU31494A priority patent/YU49065B/sh
Priority to DE0652872T priority patent/DE652872T1/de
Priority to PT00108480T priority patent/PT1020461E/pt
Priority to DE69435221T priority patent/DE69435221D1/de
Priority to PT94917244T priority patent/PT652872E/pt
Priority to UA95018075A priority patent/UA60289C2/ru
Priority to ES00108480.5T priority patent/ES2326405T5/es
Priority to EP00108479A priority patent/EP1020460B1/en
Priority to PT00108479T priority patent/PT1020460E/pt
Priority to DK94917244T priority patent/DK0652872T3/da
Priority to CA002139653A priority patent/CA2139653C/en
Priority to CA002337581A priority patent/CA2337581A1/en
Priority to ES00108479T priority patent/ES2326404T3/es
Priority to MYPI94001349A priority patent/MY121192A/en
Priority to PL94307261A priority patent/PL178994B1/pl
Priority to HU9500247A priority patent/HU226824B1/hu
Priority to SA94140756A priority patent/SA94140756B1/ar
Priority to SA05260103A priority patent/SA05260103B1/ar
Priority to EE9400363A priority patent/EE03157B1/xx
Priority to LVP-94-266A priority patent/LV11034B/en
Priority to US08/376,512 priority patent/US5714504A/en
Priority to NO950263A priority patent/NO307378B1/no
Priority to FI950377A priority patent/FI117755B/fi
Priority to US08/833,962 priority patent/US5877192A/en
Priority to GR970300012T priority patent/GR970300012T1/el
Priority to HK98109228A priority patent/HK1008330A1/xx
Priority to CN99118539A priority patent/CN1107503C/zh
Priority to US09/419,456 priority patent/US6143771A/en
Priority to US09/690,044 priority patent/US6875872B1/en
Priority to HK00107518.8A priority patent/HK1028044A1/xx
Priority to HK00107520.4A priority patent/HK1028045A1/xx
Priority to GR20010400191T priority patent/GR3035365T3/el
Priority to CY0100010A priority patent/CY2224B1/xx
Priority to JP2003317639A priority patent/JP4039999B2/ja
Priority to JP2003317637A priority patent/JP3959056B2/ja
Priority to US11/002,982 priority patent/US20060004057A1/en
Priority to FI20070002A priority patent/FI20070002A/fi
Priority to US11/679,264 priority patent/US20080312449A1/en
Priority to CL2009000805A priority patent/CL2009000805A1/es
Priority to US12/551,828 priority patent/US20100222591A1/en
Priority to NO2011009C priority patent/NO2011009I1/no
Priority to LU91870C priority patent/LU91870I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
SE19939301830A 1993-05-28 1993-05-28 New compounds SE9301830D0 (sv)

Priority Applications (73)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds
IS4161A IS1854B (is) 1993-05-28 1994-05-06 Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.
TW083104255A TW389761B (en) 1993-05-28 1994-05-11 Omeprazole and its alkaline salts with high optically purity, their pharmaceutical compositions, process for preparation including their intermediates and application in pharmaceuticals
HR940307A HRP940307B1 (en) 1993-05-28 1994-05-17 New compounds
LTIP1941A LT3287B (en) 1993-05-28 1994-05-18 Optical pure compounds, a process for their preparation and their use
IL10968494A IL109684A (en) 1993-05-28 1994-05-19 Optically pure crystalline salts of the (-) - an enantiomer of omeprazole, a process for their preparation and pharmaceutical preparations containing them
ZA943557A ZA943557B (en) 1993-05-28 1994-05-23 Highly optical pure benzimidazoles and salts thereof
DZ940055A DZ1785A1 (fr) 1993-05-28 1994-05-25 Nouveaux composés.
MA23521A MA23210A1 (fr) 1993-05-28 1994-05-26 Nouveaux composes
DE69435220T DE69435220D1 (de) 1993-05-28 1994-05-27 Das Natrium Salz des (-)-Enantiomer von Omeprazole
DK00108480.5T DK1020461T4 (en) 1993-05-28 1994-05-27 The magnesium salt of the (-) enantiomer of omeprazole and the use of this
US08/256,174 US5693818A (en) 1993-05-28 1994-05-27 Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole
RU95105587A RU2137766C1 (ru) 1993-05-28 1994-05-27 Оптически чистые na+, mg2+, li+, k+ или са2+ соли (-)-5-метокси-2[[(4-метокси-3,5-диметил-2-пиридинил)метил] сульфинил]-1h-бензимидазола, способ их получения, фармкомпозиция на их основе и промежуточное соединение
ES94917244T ES2099047T3 (es) 1993-05-28 1994-05-27 Sal de magnesio opticamente pura de un compuesto de piridinilmetilsulfinil-1h-bencimidazol.
DE69426254T DE69426254T2 (de) 1993-05-28 1994-05-27 Optisch reines magnesium-salz eines pyridinylmethylsulfinyl-1h-benzimidazole-derivats
SG1996008770A SG49283A1 (en) 1993-05-28 1994-05-27 New compounds
DK00108479T DK1020460T3 (da) 1993-05-28 1994-05-27 Natriumsalt af (-)enantiomeren af omeprazol
TNTNSN94058A TNSN94058A1 (fr) 1993-05-28 1994-05-27 Nouveaux composes
AT94917244T ATE197452T1 (de) 1993-05-28 1994-05-27 Optisch reines magnesium-salz eines pyridinylmethylsulfinyl-1h-benzimidazole-deriva s
CZ1995202A CZ287876B6 (cs) 1993-05-28 1994-05-27 Opticky čistý pyridylmethylsulfinyl-1H-benzimidazolový derivát, způsob jeho výroby, farmaceutický prostředek s jeho obsahem a meziprodukt pro jeho výrobu
KR1019950700365A KR100337274B1 (ko) 1993-05-28 1994-05-27 피리딘메틸술피닐-1h-벤즈이미다졸화합물의광학적으로순수한염
PCT/SE1994/000509 WO1994027988A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds
SI9420002A SI9420002B (sl) 1993-05-28 1994-05-27 Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin
NZ266915A NZ266915A (en) 1993-05-28 1994-05-27 Optically pure salts of (+)- and (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] -sulphinyl]-1h-benzimidazole; pharmaceutical compositions (omeprazole)
JP50055395A JP3549111B2 (ja) 1993-05-28 1994-05-27 新規な化合物
CN94190335A CN1055469C (zh) 1993-05-28 1994-05-27 旋光纯的吡啶甲基亚磺酰基－1h－苯并咪唑类化合物的盐、及其制法和应用
SI9420085A SI22752B (sl) 1993-05-28 1994-05-27 Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin
AU69024/94A AU676337C (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds
SK101-95A SK282524B6 (sk) 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu
EP00108480.5A EP1020461B2 (en) 1993-05-28 1994-05-27 Magnesium salt of the (-)-enantiomer of omeprazole and its use
EP94917244A EP0652872B1 (en) 1993-05-28 1994-05-27 Optically pure magnesium -salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
YU31494A YU49065B (sh) 1993-05-28 1994-05-27 Omeprazol enantiomeri, postupak za njihovo dobijanje, farmaceutski proizvodi i njihova upotreba u medicini
DE0652872T DE652872T1 (de) 1993-05-28 1994-05-27 Optisch reine salze von pyridinylmethylsulfinyl-1h-benzimidazole-derivaten.
PT00108480T PT1020461E (pt) 1993-05-28 1994-05-27 Sal de magnésio do enantiómero (-) de omeprazole
DE69435221T DE69435221D1 (de) 1993-05-28 1994-05-27 Magnesiumsalz des (-)-Enantiomers von Omeprazol und dessen Verwendung
PT94917244T PT652872E (pt) 1993-05-28 1994-05-27 Sal de magnesio do composto piridinil metil sulfinil-1h-benzimidazole opticamente puro
UA95018075A UA60289C2 (ru) 1993-05-28 1994-05-27 Оптически чистые соли (-)-5-метокси-2-[[(4-метокси-3,5-диметил-2-пиридинил)метил]сульфинил]-1h-бензимидазолу, способ их получения, промежуточные соединения и фармацевтическая композиция
ES00108480.5T ES2326405T5 (es) 1993-05-28 1994-05-27 Sal de magnesio del enantiómero(-) del omeprazol y su uso
EP00108479A EP1020460B1 (en) 1993-05-28 1994-05-27 The sodium salt of the (-)-enantiomer of omeprazole
PT00108479T PT1020460E (pt) 1993-05-28 1994-05-27 Sal de sódio do enantiómero (-) de omeprazole
DK94917244T DK0652872T3 (da) 1993-05-28 1994-05-27 Optisk rent magnesiumsalt af pyridinylmethylsulfinyl-1H-benzimidazolforbindelse
CA002139653A CA2139653C (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih- benzimidazole compounds
CA002337581A CA2337581A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds and intermediates in the preparation therefor
ES00108479T ES2326404T3 (es) 1993-05-28 1994-05-27 Sal sodica del enantiomero (-) de omeprazol.
MYPI94001349A MY121192A (en) 1993-05-28 1994-05-27 New compounds.
PL94307261A PL178994B1 (pl) 1993-05-28 1994-05-27 Optycznie czyste sole zwiazków pirydynylometylosulfinylo-1H-benzimidazolu i srodek farmaceutyczny je zawierajacy PL PL PL PL PL PL PL
HU9500247A HU226824B1 (en) 1993-05-28 1994-05-27 Optically active salts of pyridinyl-methyl-sulfinyl-1h-benzimidazol derivatives, pharmaceutical compositions containing them and process for producing them
SA94140756A SA94140756B1 (ar) 1993-05-28 1994-06-04 ملح magnesium نقي ضوئياً لمركب pyridinylmethyl sulfinyl- 1H- benzimidazole
SA05260103A SA05260103B1 (ar) 1993-05-28 1994-06-04 ملح الصوديوم للمتشاكل -(-) للأومبرازول
EE9400363A EE03157B1 (et) 1993-05-28 1994-11-17 Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
LVP-94-266A LV11034B (en) 1993-05-28 1994-12-30 Optically pure salts of pyridinilmethyl sulfinyl-1h-benzimidazole compounds
US08/376,512 US5714504A (en) 1993-05-28 1995-01-23 Compositions
NO950263A NO307378B1 (no) 1993-05-28 1995-01-24 Optisk rene salter av pyridinylmetylsulfinyl-1H- benzimidazolforbindelser, fremgangsmåte for deres fremstilling, farmasøytisk preparat inneholdende slike forbindelser og deres anvendelse samt mellomprodukter
FI950377A FI117755B (fi) 1993-05-28 1995-01-27 Menetelmä pyridinyylimetyylisulfinyyli-1H-bentsimidatsoliyhdisteen terapeuttisesti aktiivisen, optisesti puhtaan natrium- tai magnesiumsuolan valmistamiseksi
US08/833,962 US5877192A (en) 1993-05-28 1997-04-11 Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
GR970300012T GR970300012T1 (en) 1993-05-28 1997-05-30 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds.
HK98109228A HK1008330A1 (en) 1993-05-28 1998-07-17 Optically pure magnesium-salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
CN99118539A CN1107503C (zh) 1993-05-28 1999-09-03 一种旋光纯化合物的药用
US09/419,456 US6143771A (en) 1993-05-28 1999-10-15 Compounds
US09/690,044 US6875872B1 (en) 1993-05-28 2000-10-16 Compounds
HK00107518.8A HK1028044A1 (en) 1993-05-28 2000-11-23 Magnesium salt of the (-)-enantiomer of omeprazole and its use
HK00107520.4A HK1028045A1 (en) 1993-05-28 2000-11-23 The sodium salt of the (-)-enantiomer of omeprazole
GR20010400191T GR3035365T3 (en) 1993-05-28 2001-02-05 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds.
CY0100010A CY2224B1 (en) 1993-05-28 2001-05-22 Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds
JP2003317639A JP4039999B2 (ja) 1993-05-28 2003-09-10 新規な化合物の製造方法
JP2003317637A JP3959056B2 (ja) 1993-05-28 2003-09-10 新規な化合物
US11/002,982 US20060004057A1 (en) 1993-05-28 2004-12-01 New compounds
FI20070002A FI20070002A (fi) 1993-05-28 2007-01-02 Pyridinyylimetyylisulfinyyli-1H-bentsimidatsoliyhdisteiden optisesti puhtaat suolat
US11/679,264 US20080312449A1 (en) 1993-05-28 2007-02-27 New Compounds
CL2009000805A CL2009000805A1 (es) 1993-05-28 2009-04-02 Composicion farmaceutica que comprende a una sal sodica del enantiomero (-) de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1h-bencimidazol ((-)-omeprazol); y su uso en la inhibicion de la secrecion de acido gastrico y para tratar enfermedades inflamatorias gastrointestinales. (divisional solicitud 3570-00).
US12/551,828 US20100222591A1 (en) 1993-05-28 2009-09-01 New Compounds
NO2011009C NO2011009I1 (no) 1993-05-28 2011-06-07 Naproksen- og esomeprazoltabletter med modifisert frisetting
LU91870C LU91870I2 (fr) 1993-05-28 2011-09-19 Une combinaison de produit comprenant du naproxèneet un sel de magnésium d'esomeprazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Publications (1)

Publication Number Publication Date
SE9301830D0 true SE9301830D0 (sv) 1993-05-28

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Country Status (43)

Country Link
US (5) US5693818A (ru)
EP (3) EP1020460B1 (ru)
JP (3) JP3549111B2 (ru)
KR (1) KR100337274B1 (ru)
CN (2) CN1055469C (ru)
AT (1) ATE197452T1 (ru)
CA (2) CA2337581A1 (ru)
CL (1) CL2009000805A1 (ru)
CY (1) CY2224B1 (ru)
CZ (1) CZ287876B6 (ru)
DE (4) DE652872T1 (ru)
DK (3) DK1020460T3 (ru)
DZ (1) DZ1785A1 (ru)
EE (1) EE03157B1 (ru)
ES (3) ES2326404T3 (ru)
FI (2) FI117755B (ru)
GR (2) GR970300012T1 (ru)
HK (3) HK1008330A1 (ru)
HR (1) HRP940307B1 (ru)
HU (1) HU226824B1 (ru)
IL (1) IL109684A (ru)
IS (1) IS1854B (ru)
LT (1) LT3287B (ru)
LU (1) LU91870I2 (ru)
LV (1) LV11034B (ru)
MA (1) MA23210A1 (ru)
MY (1) MY121192A (ru)
NO (2) NO307378B1 (ru)
NZ (1) NZ266915A (ru)
PL (1) PL178994B1 (ru)
PT (3) PT1020461E (ru)
RU (1) RU2137766C1 (ru)
SA (2) SA94140756B1 (ru)
SE (1) SE9301830D0 (ru)
SG (1) SG49283A1 (ru)
SI (2) SI9420002B (ru)
SK (1) SK282524B6 (ru)
TN (1) TNSN94058A1 (ru)
TW (1) TW389761B (ru)
UA (1) UA60289C2 (ru)
WO (1) WO1994027988A1 (ru)
YU (1) YU49065B (ru)
ZA (1) ZA943557B (ru)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
CN1138534C (zh) * 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
EE04576B1 (et) * 1997-12-08 2006-02-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
PT1131316E (pt) 1998-11-18 2004-10-29 Astrazeneca Ab Processo quimico e formulacao farmaceutica melhorados
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
JP2003510348A (ja) * 1999-10-01 2003-03-18 ナトコ ファーマ リミテッド 改良された薬学的組成物およびその製造方法
EP1222922B1 (en) * 1999-10-20 2007-08-15 Eisai R&D Management Co., Ltd. Method for stabilizing benzimidazole compounds
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
PT1257269E (pt) 2000-02-24 2005-03-31 Kopran Res Lab Ltd Derivados do benzimidazole anti-ulcera estavel em relacao ao acido de administracao oral
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
BR0110926A (pt) * 2000-05-15 2004-02-17 Ranbaxy Lab Ltd Novas formas amorfas de sais de omeprazol e processo de preparação dos mesmos
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
AU2002249935A1 (en) 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
AU2002338655A1 (en) * 2001-04-13 2002-10-28 Aspinterm Llc Methods of preparing sulfinamide and sulfoxides
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1428825A4 (en) 2001-09-18 2005-03-23 Zeria Pharm Co Ltd benzimidazole derivatives
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
DE60314105T2 (de) * 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
WO2004009583A2 (en) * 2002-07-19 2004-01-29 Garst Michael E Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
JP4634144B2 (ja) * 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
US7612098B2 (en) 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2003278406A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
US7301030B2 (en) 2002-12-06 2007-11-27 Nycomed Gmbh Process for preparing (S)-pantoprazole
BRPI0310118B1 (pt) 2002-12-06 2015-10-20 Altana Pharma Ag processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20060247277A1 (en) * 2003-02-28 2006-11-02 Yatendra Kumar Polymorphs of s-omeprazole
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
NZ544173A (en) * 2003-07-15 2009-04-30 Alevium Pharmaceuticals Inc Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
MXPA06000652A (es) * 2003-07-23 2006-03-30 Altana Pharma Ag Sales alcalinas de inhibidores de bomba de protones.
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
US20060165793A1 (en) * 2003-08-04 2006-07-27 Koji Ukai Pharmaceutical preparation to be dispersed before administration
SE0302381D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
AU2003272081A1 (en) * 2003-09-25 2005-04-11 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
AU2003272086A1 (en) * 2003-10-14 2005-04-27 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US20070060621A1 (en) * 2004-02-18 2007-03-15 Hughes Patrick M Methods and compositions for the administration of prodrugs of proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US7176319B2 (en) 2004-04-28 2007-02-13 Hetero Drugs Limited Process for substituted sulfoxides
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PT1748998E (pt) 2004-05-28 2010-03-24 Hetero Drugs Ltd Novo processo de síntese estereoselectiva de sulfóxidos de benzimidazol
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
WO2006001755A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab A new esomeprazole sodium salt crystal modification
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
JP3921497B2 (ja) 2004-08-06 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール誘導体とアミンとの塩およびその製造方法
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
CA2597632C (en) 2005-03-25 2012-05-15 Livzon Pharmaceutical Group Inc. Substituted sulfoxide compounds, methods for preparing the same and use thereof
EP1885711A1 (en) 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7563812B2 (en) 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
CA2617248C (en) * 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
NZ568471A (en) 2005-12-05 2010-09-30 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
SI1973896T1 (sl) * 2005-12-28 2009-08-31 Union Quimico Farma Postopek priprave (S) - enantiomere omeprazola
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
JP2009539830A (ja) * 2006-06-07 2009-11-19 アストラゼネカ・アクチエボラーグ エソメプラゾールのアンモニウム塩の新規な製造方法
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
WO2008064015A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
MX2009007680A (es) * 2007-01-19 2011-08-03 Takeda Pharmaceuticals North America Inc Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios.
WO2008092939A2 (en) * 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
JP2010519284A (ja) 2007-02-21 2010-06-03 シプラ・リミテッド エソメプラゾールマグネシウム二水和物の調製方法
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
WO2009040825A1 (en) 2007-09-25 2009-04-02 Hetero Drugs Limited A process for preparation of enantiomerically pure esomeprazole
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) * 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010058409A2 (en) 2008-11-18 2010-05-27 Hetero Research Foundation Optical purification of esomeprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
EP2499125B1 (en) 2009-11-12 2016-01-27 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
JP5714031B2 (ja) 2010-02-12 2015-05-07 エステヴェ キミカ， エス．エー． エソメプラゾールナトリウムのナトリウム塩の調製方法
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
CN107428726B (zh) 2014-12-26 2021-03-16 国立大学法人东京大学 光学活性的质子泵抑制剂化合物的制备方法
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
WO2018191210A1 (en) * 2017-04-11 2018-10-18 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
CA3146660A1 (en) * 2019-07-16 2021-01-21 Kindred Biosciences, Inc. Equine esomeprazole formulations and methods of use
WO2021039800A1 (ja) 2019-08-29 2021-03-04 学校法人東京理科大学 スルホキシド化合物のエナンチオマー調製方法及びエナンチオマー調製システム
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
WO1994024867A1 (en) * 1993-04-27 1994-11-10 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
CN1138534C (zh) * 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
CN1055469C (zh) 2000-08-16
CZ20295A3 (en) 1995-10-18
JP3549111B2 (ja) 2004-08-04
DZ1785A1 (fr) 2002-02-17
DK1020461T3 (da) 2009-08-10
ES2326404T3 (es) 2009-10-09
LT3287B (en) 1995-06-26
HK1028045A1 (en) 2001-02-02
EP1020460A3 (en) 2003-10-15
SG49283A1 (en) 1998-05-18
HRP940307A2 (en) 1996-12-31
EP0652872B1 (en) 2000-11-08
TNSN94058A1 (fr) 1995-04-25
NO950263D0 (no) 1995-01-24
CZ287876B6 (cs) 2001-03-14
FI950377A0 (fi) 1995-01-27
DE69426254D1 (de) 2000-12-14
KR950702553A (ko) 1995-07-29
NO2011009I1 (no) 2011-06-20
AU6902494A (en) 1994-12-20
GR3035365T3 (en) 2001-05-31
DE69426254T2 (de) 2001-06-07
CY2224B1 (en) 2003-04-18
SI9420002B (sl) 2009-12-31
EP1020460B1 (en) 2009-07-22
RU2137766C1 (ru) 1999-09-20
NO950263L (no) 1995-01-24
CL2009000805A1 (es) 2009-08-21
SI9420002A (en) 1995-08-31
ATE197452T1 (de) 2000-11-11
PT1020461E (pt) 2009-07-29
ES2099047T1 (es) 1997-05-16
LTIP1941A (en) 1994-12-27
IL109684A (en) 2002-05-23
CA2139653A1 (en) 1994-12-08
DE69435220D1 (de) 2009-09-03
CN1110477A (zh) 1995-10-18
PT652872E (pt) 2001-04-30
WO1994027988A1 (en) 1994-12-08
YU49065B (sh) 2003-08-29
FI117755B (fi) 2007-02-15
DK0652872T3 (da) 2001-03-05
DE652872T1 (de) 1997-09-04
JP2004043494A (ja) 2004-02-12
YU31494A (sh) 1997-05-28
HK1008330A1 (en) 1999-05-07
CA2139653C (en) 2001-07-10
TW389761B (en) 2000-05-11
SI22752A (sl) 2009-10-31
SI22752B (sl) 2010-01-29
DE69435221D1 (de) 2009-09-03
HUT71888A (en) 1996-02-28
HK1028044A1 (en) 2001-02-02
ES2326405T3 (es) 2009-10-09
EP1020461B2 (en) 2015-10-21
CN1107503C (zh) 2003-05-07
FI950377A (fi) 1995-01-27
MY121192A (en) 2006-01-28
SA05260103B1 (ar) 2010-01-31
MA23210A1 (fr) 1994-12-31
PL178994B1 (pl) 2000-07-31
HU9500247D0 (en) 1995-03-28
LU91870I2 (fr) 2011-11-21
EP1020461B1 (en) 2009-07-22
EP0652872A1 (en) 1995-05-17
CA2337581A1 (en) 1994-12-08
KR100337274B1 (ko) 2003-12-31
US20080312449A1 (en) 2008-12-18
DK1020460T3 (da) 2009-08-10
PT1020460E (pt) 2009-07-29
EP1020460A2 (en) 2000-07-19
GR970300012T1 (en) 1997-05-31
HRP940307B1 (en) 2001-06-30
PL307261A1 (en) 1995-05-15
FI20070002A (fi) 2007-01-02
NZ266915A (en) 1996-10-28
JP3959056B2 (ja) 2007-08-15
US5714504A (en) 1998-02-03
EE03157B1 (et) 1999-02-15
LV11034A (lv) 1996-02-20
JP2004043493A (ja) 2004-02-12
JP4039999B2 (ja) 2008-01-30
IS4161A (is) 1994-11-29
LV11034B (en) 1996-10-20
DK1020461T4 (en) 2016-02-15
SK282524B6 (sk) 2002-10-08
UA60289C2 (ru) 2003-10-15
JPH07509499A (ja) 1995-10-19
CN1259346A (zh) 2000-07-12
AU676337B2 (en) 1997-03-06
NO307378B1 (no) 2000-03-27
IL109684A0 (en) 1994-12-29
RU95105587A (ru) 1996-10-27
SK10195A3 (en) 1995-09-13
SA94140756B1 (ar) 2006-05-20
EP1020461A3 (en) 2006-10-04
HU226824B1 (en) 2009-11-30
US20100222591A1 (en) 2010-09-02
US6143771A (en) 2000-11-07
US5693818A (en) 1997-12-02
EP1020461A2 (en) 2000-07-19
ES2099047T3 (es) 2001-03-01
ZA943557B (en) 1995-04-11
ES2326405T5 (es) 2016-02-15
IS1854B (is) 2003-02-21

Similar Documents

Publication Publication Date Title
SE9301830D0 (sv) New compounds
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis